---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-25-000007"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2025-02-05T23:59:59+00:00"
generated_at: "2026-05-27T03:10:17.753281+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific Q4 revenue $4.56B (+22% YoY) beats guidance; adj EPS $0.70; FY25 organic guide 10-12%

## Summary
- Q4 net sales $4.561B (+22.4% reported, 19.5% organic); GAAP EPS $0.38, adjusted EPS $0.70 vs guidance $0.64-0.66.
- Full year 2024 net sales $16.747B (+17.6% reported); GAAP EPS $1.25, adjusted EPS $2.51.
- Cardiovascular segment grew 28.8% reported; U.S. sales up 30.7%.
- Guidance: Q1 2025 adj EPS $0.66-0.68, FY 2025 adj EPS $2.80-2.87; organic growth 10-12% for FY.
- Completed acquisitions of Axonics and Cortex; announced deals for Bolt Medical and Intera Oncology.

## SEC filing metadata
- accession: 0000885725-25-000007
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2025-02-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572525000007/0000885725-25-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572525000007/bsx-20250205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-25-000007
- JSON: https://secwatch.observer/filing/0000885725-25-000007.json
- Plain text: https://secwatch.observer/filing/0000885725-25-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.